Optimization of a mAb production process with regard to robustness and product quality using quality by design principles

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Ole Jacob Wohlenberg
  • Carlotta Kortmann
  • Katharina V. Meyer
  • Jana Schellenberg
  • Katharina Dahlmann
  • Janina Bahnemann
  • Thomas Scheper
  • Dörte Solle

Research Organisations

View graph of relations

Details

Original languageEnglish
Pages (from-to)484-494
Number of pages11
JournalEngineering in life sciences
Volume22
Issue number7
Early online date17 Jul 2022
Publication statusPublished - Jul 2022

Abstract

Quality by Design principles are well described and widely used in biopharmaceutical industry. The characterization of a monoclonal antibody (mAb) production process is crucial for novel process development and control. Yet, the application throughout the entire upstream process was rarely demonstrated. Following previously published research, this study marks the second step toward a complete process characterization and is focused on the effect of critical process parameters on the antibody production efficiency and quality of the process. In order to conduct the complex Design of Experiments approach with optimal control and comparability, the ambr®15 micro bioreactor platform was used. Investigated parameters included the pH and dissolved oxygen set points, the initial viable cell density (iVCD) as well as the N-1 duration. Various quality attributes (e.g., growth rate, viability, mAb titer, and peak proportion) were monitored and analyzed using multivariate data analysis to evaluate the parameter effects. The pH set point and the initial VCD were identified as key process parameters with strong influence on the cell growth as well as the mAb production and its proportion to the total protein concentration. For optimization and improvement in robustness of these quality attributes the pH must be increased to 7.2, while the iVCD must be lowered to 0.2 × 106 cells/mL. Based on the defined design space, additional experiments verified the results and confirmed the intact bioactivity of the antibody. Thereby, process control strategies could be tuned toward high cell maintenance and mAb production, which enable optimal downstream processing.

Keywords

    ambr®, chinese hamster ovary, monoclonal antibody, process analytical technology, quality by design

ASJC Scopus subject areas

Cite this

Optimization of a mAb production process with regard to robustness and product quality using quality by design principles. / Wohlenberg, Ole Jacob; Kortmann, Carlotta; Meyer, Katharina V. et al.
In: Engineering in life sciences, Vol. 22, No. 7, 07.2022, p. 484-494.

Research output: Contribution to journalArticleResearchpeer review

Wohlenberg OJ, Kortmann C, Meyer KV, Schellenberg J, Dahlmann K, Bahnemann J et al. Optimization of a mAb production process with regard to robustness and product quality using quality by design principles. Engineering in life sciences. 2022 Jul;22(7):484-494. Epub 2022 Jul 17. doi: 10.1002/elsc.202100172, 10.15488/12957
Wohlenberg, Ole Jacob ; Kortmann, Carlotta ; Meyer, Katharina V. et al. / Optimization of a mAb production process with regard to robustness and product quality using quality by design principles. In: Engineering in life sciences. 2022 ; Vol. 22, No. 7. pp. 484-494.
Download
@article{90bffa0e03db4f03ac43d7502776339a,
title = "Optimization of a mAb production process with regard to robustness and product quality using quality by design principles",
abstract = "Quality by Design principles are well described and widely used in biopharmaceutical industry. The characterization of a monoclonal antibody (mAb) production process is crucial for novel process development and control. Yet, the application throughout the entire upstream process was rarely demonstrated. Following previously published research, this study marks the second step toward a complete process characterization and is focused on the effect of critical process parameters on the antibody production efficiency and quality of the process. In order to conduct the complex Design of Experiments approach with optimal control and comparability, the ambr{\textregistered}15 micro bioreactor platform was used. Investigated parameters included the pH and dissolved oxygen set points, the initial viable cell density (iVCD) as well as the N-1 duration. Various quality attributes (e.g., growth rate, viability, mAb titer, and peak proportion) were monitored and analyzed using multivariate data analysis to evaluate the parameter effects. The pH set point and the initial VCD were identified as key process parameters with strong influence on the cell growth as well as the mAb production and its proportion to the total protein concentration. For optimization and improvement in robustness of these quality attributes the pH must be increased to 7.2, while the iVCD must be lowered to 0.2 × 106 cells/mL. Based on the defined design space, additional experiments verified the results and confirmed the intact bioactivity of the antibody. Thereby, process control strategies could be tuned toward high cell maintenance and mAb production, which enable optimal downstream processing.",
keywords = "ambr{\textregistered}, chinese hamster ovary, monoclonal antibody, process analytical technology, quality by design",
author = "Wohlenberg, {Ole Jacob} and Carlotta Kortmann and Meyer, {Katharina V.} and Jana Schellenberg and Katharina Dahlmann and Janina Bahnemann and Thomas Scheper and D{\"o}rte Solle",
note = "Funding Information: The authors acknowledge the financial support of the research by the Federal Ministry of Education and Research, Germany (031B0744). Open access funding enabled and organized by ProjektDEAL. ",
year = "2022",
month = jul,
doi = "10.1002/elsc.202100172",
language = "English",
volume = "22",
pages = "484--494",
journal = "Engineering in life sciences",
issn = "1618-0240",
publisher = "Wiley-VCH Verlag",
number = "7",

}

Download

TY - JOUR

T1 - Optimization of a mAb production process with regard to robustness and product quality using quality by design principles

AU - Wohlenberg, Ole Jacob

AU - Kortmann, Carlotta

AU - Meyer, Katharina V.

AU - Schellenberg, Jana

AU - Dahlmann, Katharina

AU - Bahnemann, Janina

AU - Scheper, Thomas

AU - Solle, Dörte

N1 - Funding Information: The authors acknowledge the financial support of the research by the Federal Ministry of Education and Research, Germany (031B0744). Open access funding enabled and organized by ProjektDEAL.

PY - 2022/7

Y1 - 2022/7

N2 - Quality by Design principles are well described and widely used in biopharmaceutical industry. The characterization of a monoclonal antibody (mAb) production process is crucial for novel process development and control. Yet, the application throughout the entire upstream process was rarely demonstrated. Following previously published research, this study marks the second step toward a complete process characterization and is focused on the effect of critical process parameters on the antibody production efficiency and quality of the process. In order to conduct the complex Design of Experiments approach with optimal control and comparability, the ambr®15 micro bioreactor platform was used. Investigated parameters included the pH and dissolved oxygen set points, the initial viable cell density (iVCD) as well as the N-1 duration. Various quality attributes (e.g., growth rate, viability, mAb titer, and peak proportion) were monitored and analyzed using multivariate data analysis to evaluate the parameter effects. The pH set point and the initial VCD were identified as key process parameters with strong influence on the cell growth as well as the mAb production and its proportion to the total protein concentration. For optimization and improvement in robustness of these quality attributes the pH must be increased to 7.2, while the iVCD must be lowered to 0.2 × 106 cells/mL. Based on the defined design space, additional experiments verified the results and confirmed the intact bioactivity of the antibody. Thereby, process control strategies could be tuned toward high cell maintenance and mAb production, which enable optimal downstream processing.

AB - Quality by Design principles are well described and widely used in biopharmaceutical industry. The characterization of a monoclonal antibody (mAb) production process is crucial for novel process development and control. Yet, the application throughout the entire upstream process was rarely demonstrated. Following previously published research, this study marks the second step toward a complete process characterization and is focused on the effect of critical process parameters on the antibody production efficiency and quality of the process. In order to conduct the complex Design of Experiments approach with optimal control and comparability, the ambr®15 micro bioreactor platform was used. Investigated parameters included the pH and dissolved oxygen set points, the initial viable cell density (iVCD) as well as the N-1 duration. Various quality attributes (e.g., growth rate, viability, mAb titer, and peak proportion) were monitored and analyzed using multivariate data analysis to evaluate the parameter effects. The pH set point and the initial VCD were identified as key process parameters with strong influence on the cell growth as well as the mAb production and its proportion to the total protein concentration. For optimization and improvement in robustness of these quality attributes the pH must be increased to 7.2, while the iVCD must be lowered to 0.2 × 106 cells/mL. Based on the defined design space, additional experiments verified the results and confirmed the intact bioactivity of the antibody. Thereby, process control strategies could be tuned toward high cell maintenance and mAb production, which enable optimal downstream processing.

KW - ambr®

KW - chinese hamster ovary

KW - monoclonal antibody

KW - process analytical technology

KW - quality by design

UR - http://www.scopus.com/inward/record.url?scp=85131185899&partnerID=8YFLogxK

U2 - 10.1002/elsc.202100172

DO - 10.1002/elsc.202100172

M3 - Article

AN - SCOPUS:85131185899

VL - 22

SP - 484

EP - 494

JO - Engineering in life sciences

JF - Engineering in life sciences

SN - 1618-0240

IS - 7

ER -

By the same author(s)